RESEARCH
Early is grounded in science.
The Early program is built on a deep, biological understanding of weight management. Explore the peer-reviewed research that powers our approach to sustainable weight loss.
Our Most Impactful Studies
GLP-1 Therapies: A Review of Clinical Trials
THE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
- Semaglutide (Wegovy) resulted in significant weight loss of up to 14.9% in the landmark STEP trials.
- Tirzepatide (Zepbound), a dual-action agent, achieved even greater weight loss of up to 26.6% in SURMOUNT trials.
- Earlier therapies like Liraglutide (Saxenda) demonstrated weight loss of up to 8%, establishing the foundation for GLP-1 treatment.
Full Study →
Tirzepatide Once Weekly for the Treatment of Obesity
THE NEW ENGLAND JOURNAL OF MEDICINE
- Patients on the highest dose (15mg) lost an average of 20.9% of their starting body weight over 72 weeks.
- The 10mg dose group saw an average weight loss of 19.5%, while the 5mg group lost 15.0%.
- About half of the individuals on higher doses lost 20% or more of their body weight, a result achieved by only 3% on placebo.
Full Study →
Sustained Weight Loss with Tirzepatide (3-Year Trial)
LILLY RESEARCH
- Demonstrated remarkable and sustained weight loss, with patients losing an average of 22.9% over 3 years.
- This represents the longest and most sustained weight loss observed in any major obesity medicine trial to date.
- This durable weight loss was associated with a 94% reduction in the risk of progressing to type 2 diabetes.
Full Study →
Tirzepatide for Weight Reduction in Asian Adults
THE SURMOUNT-CN RANDOMIZED CLINICAL TRIAL
- Participants lost up to 17.5% of their body weight over 52 weeks, confirming strong efficacy in this population.
- A significant 86% of individuals taking Tirzepatide lost at least 5% of their body weight.
- The study confirmed Tirzepatide as a powerful option, showing similar effectiveness to global studies.
Full Study →
More on Research
Loading...
.8f51146f.png){kind=small}
.8f8d4ed9.png){kind=small}
